Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SCSF1RDRD2FLT1FLT3FLT4HTR1BHTR1DHTR1FKDRKITMETOPRD1OPRK1OPRM1PDGFRAPDGFRBRET
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.54 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malic Acid SCHEMBL7191878 | 1.00 | TAAR1 (0.63) | TAAR1GABBR2GABBR1SMN1; SMN2FFAR1 | |
| Malic Acid SCHEMBL6787423 | 1.00 | TAAR1 (0.63) | TAAR1GABBR2GABBR1SMN1; SMN2FFAR1 | |
| Malic Acid SCHEMBL339196 | 1.00 | TAAR1 (0.63) | TAAR1GABBR2GABBR1SMN1; SMN2FFAR1 | |
| Bicarbonate SCHEMBL9490583 | 0.84 | TAAR1 (0.83) | TAAR1GABBR2GABBR1FFAR1GAA | |
| Isopropylbenzene SCHEMBL6787420 | 0.83 | SMN1; SMN2 (0.54) | GABBR2GABBR1SMN1; SMN2FFAR1CYP2C19 | |
| SCHEMBL240503 | 0.80 | TAAR1 (1.00) | TAAR1AOC3 | |
| SCHEMBL238388 | 0.80 | TAAR1 (1.00) | TAAR1AOC3 | |
| SCHEMBL2107 | 0.80 | TAAR1 (1.00) | TAAR1AOC3 | |
| Mandelic Acid SCHEMBL3711577 | 0.79 | LMNA (0.69) | GABBR2GABBR1SMN1; SMN2FFAR1CYP2C19 | |
| Glycine SCHEMBL8726564 | 0.79 | FFAR1 (0.62) | TAAR1GABBR2GABBR1FFAR1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097652-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2012-01-17 | — | — | US | disclosed |
| US-20100010090-A1 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY | 2010-01-14 | — | — | US | disclosed |
| EP-2102153-A1 | AMPA RECEPTOR POTENTIATORS | Eli Lilly & Company (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008073789-A1 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2008-06-19 | — | — | WO | disclosed |
| CN-1769266-A | Process for preparing biphenyl compounds | LILLY CO ELI (US) | 2006-05-10 | — | — | CN | disclosed |
| US-6984756-B2 | Process for preparing biphenyl compounds | ELI LILLY AND COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1294683-B1 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | LILLY CO ELI (US) | 2005-11-30 | — | — | EP | disclosed |
| CN-1219756-C | Process for producing biphenyl compound | LILLY CO ELI (US) | 2005-09-21 | — | — | CN | disclosed |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | BLEAKMAN DAVID (US) | 2004-11-25 | — | — | US | disclosed |
| US-6803484-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2004-10-12 | — | — | US | disclosed |
| EP-1294683-A2 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1292311-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002018329-A1 | ACETYLENIC SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002014294-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001090057-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090055-A2 | A PROCESS FOR PREPARING BIPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090056-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010090-A1 | AMPA RECEPTOR POTENTIATORS | GRIN1, GRIK2, GRIK1 | TAAR1 109/4885GABBR2 64/4885GABBR1 65/4885 |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | GABRE, SCN2A, SCN1A | TAAR1 1353/4885GABBR2 21/4885GABBR1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.